A detailed history of Rhumbline Advisers transactions in Novavax Inc stock. As of the latest transaction made, Rhumbline Advisers holds 195,440 shares of NVAX stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
195,440
Previous 199,909 2.24%
Holding current value
$1.8 Million
Previous $2.53 Million 2.45%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$10.71 - $17.11 $47,862 - $76,464
-4,469 Reduced 2.24%
195,440 $2.47 Million
Q2 2024

Aug 01, 2024

BUY
$3.89 - $20.97 $219,100 - $1.18 Million
56,324 Added 39.23%
199,909 $2.53 Million
Q1 2024

May 09, 2024

BUY
$3.76 - $6.02 $48,522 - $77,688
12,905 Added 9.88%
143,585 $686,000
Q4 2023

Feb 08, 2024

BUY
$4.8 - $7.67 $31,382 - $50,146
6,538 Added 5.27%
130,680 $627,000
Q3 2023

Nov 09, 2023

BUY
$6.81 - $9.74 $5,679 - $8,123
834 Added 0.68%
124,142 $898,000
Q2 2023

Aug 08, 2023

BUY
$6.67 - $9.52 $168,317 - $240,237
25,235 Added 25.73%
123,308 $916,000
Q1 2023

May 11, 2023

BUY
$5.76 - $12.48 $92,476 - $200,366
16,055 Added 19.57%
98,073 $680,000
Q4 2022

Feb 14, 2023

SELL
$8.86 - $25.04 $97 - $275
-11 Reduced 0.01%
82,018 $843,000
Q3 2022

Nov 10, 2022

BUY
$18.2 - $76.12 $38,201 - $159,775
2,099 Added 2.63%
82,029 $1.49 Million
Q2 2022

Aug 11, 2022

BUY
$36.28 - $75.29 $278,557 - $578,076
7,678 Added 10.63%
79,930 $4.11 Million
Q1 2022

May 12, 2022

SELL
$69.73 - $142.9 $437,207 - $895,983
-6,270 Reduced 7.99%
72,252 $5.32 Million
Q4 2021

Feb 10, 2022

BUY
$134.56 - $217.97 $572,014 - $926,590
4,251 Added 5.72%
78,522 $11.2 Million
Q3 2021

Nov 12, 2021

SELL
$177.8 - $270.58 $172,999 - $263,274
-973 Reduced 1.29%
74,271 $15.4 Million
Q2 2021

Aug 05, 2021

SELL
$121.0 - $257.67 $2.65 Million - $5.64 Million
-21,870 Reduced 22.52%
75,244 $16 Million
Q1 2021

May 06, 2021

SELL
$112.98 - $319.93 $495,304 - $1.4 Million
-4,384 Reduced 4.32%
97,114 $17.6 Million
Q4 2020

Feb 10, 2021

BUY
$78.74 - $139.5 $663,620 - $1.18 Million
8,428 Added 9.06%
101,498 $11.3 Million
Q3 2020

Nov 12, 2020

SELL
$79.44 - $178.51 $1.16 Million - $2.61 Million
-14,639 Reduced 13.59%
93,070 $10.1 Million
Q2 2020

Aug 13, 2020

BUY
$13.86 - $83.61 $812,376 - $4.9 Million
58,613 Added 119.38%
107,709 $8.98 Million
Q1 2020

May 06, 2020

BUY
$3.93 - $16.0 $62,872 - $255,968
15,998 Added 48.34%
49,096 $667,000
Q4 2019

Feb 05, 2020

SELL
$3.69 - $5.22 $1,217 - $1,722
-330 Reduced 0.99%
33,098 $132,000
Q3 2019

Oct 23, 2019

BUY
$4.02 - $7.84 $12,534 - $24,445
3,118 Added 10.29%
33,428 $168,000
Q2 2019

Aug 14, 2019

BUY
$4.93 - $12.2 $149,428 - $369,782
30,310 New
30,310 $178,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $722M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.